Agenus Inc. Share Price & Technical Analysis
AGEN · $3.11 (-1.58%)
Healthcare / Biotechnology
$3.11
-1.58%
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-21% return in May, 18% avg return in past 3 year May month.
3% return in 2026, -42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | 18% | 3% | 15% | -21% | – | – | – | – | – | – | – | 3% |
| 25 | 36% | -20% | -48% | 93% | 17% | 31% | 22% | -24% | -7% | 5% | 15% | -30% | 91% |
| 24 | -20% | -1% | -15% | 3% | 33% | 7% | -64% | -15% | 6% | -22% | -19% | -23% | -131% |
| 23 | 8% | -21% | -26% | 1% | 3% | 4% | -6% | -9% | -19% | -29% | -1% | 6% | -87% |
| 22 | -16% | -3% | -6% | -26% | -10% | 16% | 34% | 6% | -24% | 20% | 6% | -11% | -14% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$135.41M
P/E ratio
—
52W high
$7.34
52W low
$2.71
Volume
9,01,410
Beta
1.60
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Agenus Inc. share price today?
- Agenus Inc. (AGEN) last traded around $3.11 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AGEN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AGEN. Download the app for real-time alerts.
- How can I analyze Agenus Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.